Torrent Pharmaceuticals LimitedQ1 FY27 Results & Financial Update
Torrent Pharmaceuticals Limited: Q1 FY27 consolidated results and company financials – revenue ₹4,921.00 Cr, PAT ₹566.00 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Torrent Pharmaceuticals price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Torrent Pharmaceuticals Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
For the first quarter of financial year 2027 (ended 30 June 2026), Torrent Pharmaceuticals recorded total consolidated revenue from operations of INR 4,921 crore.
Total income for the quarter stood at INR 4,909 crore, incorporating other income of negative INR 12 crore.
Profit before tax (PBT) for Q1 FY27 was reported at INR 733 crore, after accounting for finance costs and depreciation charges.
The company registered a tax expense of INR 167 crore for the period, leading to a consolidated net profit after tax (PAT) of INR 566 crore.
Basic and diluted earnings per share (EPS) for the quarter were documented at INR 14.87.
Financing and capital asset retention costs for the period included finance costs of INR 305 crore and depreciation and amortization expenses of INR 593 crore.
During the quarter ended 30 June 2026, corresponding to Q1 FY27, Torrent Pharmaceuticals recorded a consolidated revenue from operations of INR 4,921 crore.
01 · Business model
What does Torrent Pharmaceuticals do?
Torrent Pharmaceuticals Limited is a major Indian multinational pharmaceutical company engaged in the research, development, manufacturing, and commercialization of branded and generic pharmaceutical formulations.
The company operates significant therapeutic portfolios spanning chronic and acute segments, holding strong market positions in key domestic and international prescription drug markets.
Torrent Pharma derives its revenue from diverse geographic operations, supported by advanced manufacturing facilities that cater to institutional clients, pharmacies, and healthcare providers globally.
The group's operational model focuses on specialized therapy areas, brand building in emerging and developed markets, and continuous compliance-driven manufacturing enhancement.
02 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹4,921.00 Cr |
| Total income | ₹4,909.00 Cr |
| Profit before tax | ₹733.00 Cr |
| Profit after tax | ₹566.00 Cr |
| EPS | ₹14.87 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 11.5% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 14.9% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations reached INR 4,921 crore for the quarter ended 30 June 2026.
Total income for Q1 FY27 stood at INR 4,909 crore, reflecting operating revenue combined with other income elements.
What drove margins
Finance costs for the quarter were reported at INR 305 crore, impacting overall bottom-line profitability.
Depreciation and amortization expenses accounted for INR 593 crore during the quarter.
Tax expenses for the period stood at INR 167 crore, corresponding to a profit before tax of INR 733 crore.
Depreciation and amortisation expenses for the quarter were recorded at INR 593 crore, impacting bottom-line profitability.
The company incurred finance costs amounting to INR 305 crore during the quarter.
Other income was negative at INR 12 crore for the quarter, exerting a minor drag on total income relative to operating revenue.
04 · Items worth noticing
The line items that can distort a quick read
Other income for the quarter was reported at negative INR 12 crore.
05 · Beyond the numbers
What changed beyond the numbers
Reported update
Filing Submission
The financial results for Q1 FY27 were submitted through official exchange structured filings on 30 July 2026.
06 · Key Q&A
The quarter, answered directly
What does Torrent Pharmaceuticals do?
Torrent Pharmaceuticals Limited is a major Indian multinational pharmaceutical company engaged in the research, development, manufacturing, and commercialization of branded and generic pharmaceutical formulations.
What is the clearest takeaway from Q1 FY27?
For the first quarter of financial year 2027 (ended 30 June 2026), Torrent Pharmaceuticals recorded total consolidated revenue from operations of INR 4,921 crore.
What drove revenue or demand?
Revenue from operations reached INR 4,921 crore for the quarter ended 30 June 2026.
What mattered most for margins or profitability?
Finance costs for the quarter were reported at INR 305 crore, impacting overall bottom-line profitability.
What changed operationally beyond the headline numbers?
The financial results for Q1 FY27 were submitted through official exchange structured filings on 30 July 2026.
What should the next disclosure help confirm?
Monitor upcoming quarterly financial filings and disclosures for sequential trends in revenue, operating margins, and profit progression.
07 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
08 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsequent Financial Disclosures: Monitor upcoming quarterly financial filings and disclosures for sequential trends in revenue, operating margins, and profit progression.
- 02
Finance Cost and Depreciation Trajectory: Track future filings for movements in finance costs and depreciation charges relative to revenue growth.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.